{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:05:44Z","timestamp":1790928344843,"version":"4.1.0"},"reference-count":30,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Chondrosarcoma is a clinically heterogeneous malignancy, and the prognostic role of its genetic features remains incompletely defined. While isocitrate dehydrogenase (IDH) mutations are well characterized, the significance of less common alterations\u2014particularly telomerase reverse transcriptase (TERT) promoter mutations\u2014remains unclear. This study aimed to define the genomic profile of chondrosarcoma and evaluate the prognostic relevance of TERT mutations, alone and in combination with IDH mutations. Methods: We retrospectively analyzed 91 patients with chondrosarcoma, including 54 patients with available next-generation sequencing data for genomic analyses. Tumors were assessed for mutations in IDH, TERT, TP53, and groups of genes involved in key cellular functions (e.g., cell cycle control, chromatin regulation). Associations with tumor characteristics were evaluated, recurrence outcomes were assessed using logistic regression, and overall survival was analyzed using Kaplan\u2013Meier and Cox models adjusted for tumor subtype, grade, and size. Results: IDH mutations were present in 52% of tumors; other alterations included TP53 (16%), TERT (7.7%), chromatin-related genes (14%), and cell cycle genes (8.8%). TERT mutations were enriched in dedifferentiated tumors (p = 0.017) and occurred exclusively in grade 3 disease (\u201cp &lt; 0.001\u201d). TERT-mutant tumors were associated with worse overall survival upon unadjusted analysis (HR 7.02, p = 0.024), but not after adjustment (HR 3.81, p = 0.160). All TERT mutations co-occurred with IDH mutations, and this subgroup had particularly poor survival (HR 7.76, p = 0.022), albeit limited by small numbers. Conclusions: These findings suggest that specific mutations, alone or in combination, may influence clinical outcomes by reflecting more aggressive tumor biology. TERT mutations, particularly with concurrent IDH mutations, may identify high-risk patients and complement established prognostic factors. Further validation is needed.<\/jats:p>","DOI":"10.3390\/cancers18142272","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:05:07Z","timestamp":1784163907000},"page":"2272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Role of TERT Mutations in Chondrosarcoma: Associations with Dedifferentiation, Survival, and IDH\/TERT Co-Mutations"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0199-3049","authenticated-orcid":false,"given":"Alyan","family":"Zafar","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Musculoskeletal Oncology Division, University of Miami Heath System, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Ference","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Musculoskeletal Oncology Division, University of Miami Heath System, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke M.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Musculoskeletal Oncology Division, University of Miami Heath System, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-2143","authenticated-orcid":false,"given":"Sergio Jose Torralbas","family":"Fitz","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Musculoskeletal Oncology Division, University of Miami Heath System, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6916-8042","authenticated-orcid":false,"given":"Francis J.","family":"Hornicek","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Musculoskeletal Oncology Division, University of Miami Heath System, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7115-073X","authenticated-orcid":false,"given":"H. Thomas","family":"Temple","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Musculoskeletal Oncology Division, University of Miami Heath System, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e250017","DOI":"10.6004\/jnccn.2025.0017","article-title":"Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology","volume":"23","author":"Biermann","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2106\/JBJS.H.00416","article-title":"Chondrosarcoma in the United States (1973 to 2003): An analysis of 2890 cases from the SEER database","volume":"91","author":"Giuffrida","year":"2009","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2106\/00004623-199903000-00004","article-title":"Chondrosarcoma of bone: An assessment of outcome","volume":"81","author":"Lee","year":"1999","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/cncr.21936","article-title":"Dedifferentiated central chondrosarcoma","volume":"106","author":"Staals","year":"2006","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/jclinpath-2018-205071","article-title":"Biomarkers of chondrosarcoma","volume":"71","author":"Jeong","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Evola, F.R., Costarella, L., Pavone, V., Caff, G., Cannav\u00f2, L., Sessa, A., Avondo, S., and Sessa, G. (2017). Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00150"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"key":"ref_9","first-page":"326","article-title":"The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation","volume":"1846","author":"Molenaar","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/ng.1004","article-title":"Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome","volume":"43","author":"Pansuriya","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","article-title":"Biological Role and Therapeutic Potential of IDH Mutations in Cancer","volume":"34","author":"Waitkus","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41467-017-01026-0","article-title":"The driver landscape of sporadic chordoma","volume":"8","author":"Tarpey","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-019-12525-7","article-title":"Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression","volume":"10","author":"Nicolle","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/PAS.0b013e31827ab703","article-title":"Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1\/2 mutations","volume":"37","author":"Kerr","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41379-021-00848-0","article-title":"TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma","volume":"34","author":"Zhang","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","article-title":"The regulations of telomerase reverse transcriptase (TERT) in cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/2767-9764.CRC-22-0397","article-title":"Distinct IDH1\/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma","volume":"3","author":"Dermawan","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13073-022-01084-0","article-title":"A genetic model for central chondrosarcoma evolution correlates with patient outcome","volume":"14","author":"Cross","year":"2022","journal-title":"Genome Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00262-024-03822-2","article-title":"Disruptions in antigen processing and presentation machinery on sarcoma","volume":"73","author":"Renne","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bravo Thompson, H., Chattopadhyay, P., Subhawong, T., Palmer, M.-C., Torralbas Fitz, S., Crawford, B., Rosenberg, A., Temple, H.T., and Jonczak, E. (2026). MRI-Based Delta Necrosis as a Prognostic Marker Following Neoadjuvant Chemotherapy in South Tissue Sarcoma. Cancers, 18.","DOI":"10.3390\/cancers18020291"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jor.2025.01.030","article-title":"Rethinking tumor viability as prognostic factor in soft tissue sarcoma","volume":"68","author":"Montreuil","year":"2025","journal-title":"J. Orthop."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Walter, S.G., Kn\u00f6ll, P., Eysel, P., Quaas, A., Gaisendrees, C., Ni\u00dfler, R., and Hieggelke, L. (2023). Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies. Cancers, 15.","DOI":"10.3390\/cancers15092556"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Walker, R.L., Hornicek, F.J., and Duan, Z. (2025). Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine. Cancers, 17.","DOI":"10.3390\/cancers17162689"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2400592","DOI":"10.1200\/PO-24-00592","article-title":"Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets","volume":"9","author":"Wagner","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zaj\u0105c, A.E., Kope\u0107, S., Szostakowski, B., Spa\u0142ek, M.J., Fiedorowicz, M., Bylina, E., Filipowicz, P., Szumera-Cie\u0107kiewicz, A., Tysarowski, A., and Czarnecka, A.M. (2021). Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers, 13.","DOI":"10.3390\/cancers13102390"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41379-018-0098-3","article-title":"hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality","volume":"31","author":"Lin","year":"2018","journal-title":"Mod. Pathol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:11:52Z","timestamp":1784164312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":30,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142272"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142272","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}